Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ngoc H Tan

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Trials|August 6, 2024
Evaluation of a group-based online informed consent conversation (eConsent) in participants from a low-risk vaccination clinical trialNgoc H Tan, Melvin Lafeber, Roos S G Sablerolles, et al.
The Lancet. Infectious Diseases|June 23, 2024
Profiling the SARS-CoV-2-specific T-cell responseDaryl Geers, Lennert Gommers, Ngoc H Tan, et al.
The Journal of Infection|August 10, 2024
Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariantsHolly A Fryer, Daryl Geers, Lennert Gommers, et al.
AIDS (London, England)|May 24, 2024
Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the NetherlandsMarlou J Jongkees, Ngoc H Tan, Daryl Geers, et al.
The Lancet. Microbe|April 16, 2026
Characterisation of immune responses targeting highly pathogenic avian influenza A(H5) viruses in health-care workers in the Netherlands: an observational, cross-sectional analysisMark A Power, Willemijn F Rijnink, Widia Soochit, et al.
Frontiers in Immunology|December 16, 2022
Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocolNgoc H Tan, Roos S G Sablerolles, Wim J R Rietdijk, et al.
Nature Communications|May 18, 2024
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boostersLuca M Zaeck, Ngoc H Tan, Wim J R Rietdijk, et al.
The Lancet. Infectious Diseases|April 23, 2023
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trialNgoc H Tan, Daryl Geers, Roos S G Sablerolles, et al.
The Journal of Infection|January 10, 2026
Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccinationDaryl Geers, Muriel Aguilar-Bretones, Luca M Zaeck, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Trials|August 6, 2024
Evaluation of a group-based online informed consent conversation (eConsent) in participants from a low-risk vaccination clinical trialNgoc H Tan, Melvin Lafeber, Roos S G Sablerolles, et al.
The Lancet. Infectious Diseases|June 23, 2024
Profiling the SARS-CoV-2-specific T-cell responseDaryl Geers, Lennert Gommers, Ngoc H Tan, et al.
The Journal of Infection|August 10, 2024
Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariantsHolly A Fryer, Daryl Geers, Lennert Gommers, et al.
AIDS (London, England)|May 24, 2024
Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the NetherlandsMarlou J Jongkees, Ngoc H Tan, Daryl Geers, et al.
The Lancet. Microbe|April 16, 2026
Characterisation of immune responses targeting highly pathogenic avian influenza A(H5) viruses in health-care workers in the Netherlands: an observational, cross-sectional analysisMark A Power, Willemijn F Rijnink, Widia Soochit, et al.
Frontiers in Immunology|December 16, 2022
Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocolNgoc H Tan, Roos S G Sablerolles, Wim J R Rietdijk, et al.
Nature Communications|May 18, 2024
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boostersLuca M Zaeck, Ngoc H Tan, Wim J R Rietdijk, et al.
The Lancet. Infectious Diseases|April 23, 2023
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trialNgoc H Tan, Daryl Geers, Roos S G Sablerolles, et al.
The Journal of Infection|January 10, 2026
Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccinationDaryl Geers, Muriel Aguilar-Bretones, Luca M Zaeck, et al.
Pageof 1